UNLABELLED: The aim of this study was to look at the impact of the number of sites with tumour involvement on outcome for patients with stage IIIA endometrioid-type endometrial carcinoma. PATIENTS AND METHODS: 141 patients stage IIIA were included. A central histopathological review was performed. Patients staged solely on the presence of a positive peritoneal washing were excluded. Follow-up ranged from 2 to 217 months with a median of 43 months. Endpoints of the study were locoregional recurrence rates, distant metastasis-free survival (DMFS), disease-free survival (DFS) and disease-specific survival (DSS). RESULTS: In multivariate analyses the number of involved sites showed to be the only independent significant variable for DMFS, DFS, and DSS with a Hazard Ratio of 2.1, 2.2, and 2.2, respectively. The DSS was significantly related to the number of involved sites, with a 5-year DSS of 70.4% for one site, 42.8% for two sites, and 43.9% for three sites, respectively (p=0.001). CONCLUSION: The number of involved sites outside the corpus uterine for stage IIIA seems to be a strong negative prognostic factor for stage IIIA endometrial carcinoma. Copyright 2009 Elsevier Inc. All rights reserved.
UNLABELLED: The aim of this study was to look at the impact of the number of sites with tumour involvement on outcome for patients with stage IIIA endometrioid-type endometrial carcinoma. PATIENTS AND METHODS: 141 patients stage IIIA were included. A central histopathological review was performed. Patients staged solely on the presence of a positive peritoneal washing were excluded. Follow-up ranged from 2 to 217 months with a median of 43 months. Endpoints of the study were locoregional recurrence rates, distant metastasis-free survival (DMFS), disease-free survival (DFS) and disease-specific survival (DSS). RESULTS: In multivariate analyses the number of involved sites showed to be the only independent significant variable for DMFS, DFS, and DSS with a Hazard Ratio of 2.1, 2.2, and 2.2, respectively. The DSS was significantly related to the number of involved sites, with a 5-year DSS of 70.4% for one site, 42.8% for two sites, and 43.9% for three sites, respectively (p=0.001). CONCLUSION: The number of involved sites outside the corpus uterine for stage IIIA seems to be a strong negative prognostic factor for stage IIIA endometrial carcinoma. Copyright 2009 Elsevier Inc. All rights reserved.
Authors: Melissa A Geller; Joseph J Ivy; Rahel Ghebre; Levi S Downs; Patricia L Judson; Linda F Carson; Amy L Jonson; Kathryn Dusenbery; Rachel Isaksson Vogel; Matthew P Boente; Peter A Argenta Journal: Gynecol Oncol Date: 2011-01-15 Impact factor: 5.482
Authors: Jan J Jobsen; Lambert Naudin Ten Cate; Marnix L M Lybeert; Astrid Scholten; Elzbieta M van der Steen-Banasik; Job van der Palen; Marika C Stenfert Kroese; Annerie Slot; Eltjo M J Schutter; Sabine Siesling Journal: Obstet Gynecol Int Date: 2011-05-04
Authors: Mee Sun Yoon; Seung Jae Huh; Hak Jae Kim; Young Seok Kim; Yong Bae Kim; Joo-Young Kim; Jong-Hoon Lee; Hun Jung Kim; Jihye Cha; Jin Hee Kim; Juree Kim; Won Sup Yoon; Jin Hwa Choi; Mison Chun; Youngmin Choi; Kang Kyoo Lee; Myungsoo Kim; Jae-Uk Jeong; Sei Kyung Chang; Won Park Journal: Cancer Res Treat Date: 2015-10-29 Impact factor: 4.679